February 17, 2022
Vifor Pharma reports sustained growth in 2021
Net sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Business
February 15, 2022
Sustainable packaging concepts for pharmaceutical products from Faller Packaging
In the pharmaceutical industry, the issue of sustainability is increasingly coming into focus, forcing packaging manufacturers to rethink their strategies…
February 15, 2022
Marinomed receives € 6 M with final tranche of financing agreement with EIB to invest in proprietary R&D pipeline
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today…
February 11, 2022
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
– Partnership leverages Theramex’s leading women’s health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix…
February 10, 2022
AstraZeneca reports $37,417M revenue; 10% driven by COVID-19 vaccine
AstraZeneca has reported increase of revenue of 41% (38 at CER) to $37,417 million in results for Q4 and full year 2021 released on Thursday. This includes revenue from COVID-19 vaccine of $3,981 million. The increase of revenue has been driven by five medicines: Tagrisso ($5bn+), Farxiga ($3bn+), Lynparza ($2bn+), Calquence ($1bn+) and Fasenra ($1bn+).
February 9, 2022
AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M
AiCuris Anti-infective Cures AG (AiCuris), a company focused to the discovery and development of drugs against infectious diseases, and Hybridize…
February 9, 2022
EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies
BEIJING & SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies…
February 9, 2022
Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants
FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of…
February 8, 2022
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savingsCAMBRIDGE, Mass and…
February 7, 2022
Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims
TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)…